Dendritic cells as orchestrators of anticancer immunity and immunotherapy

Nature Reviews Clinical Oncology, Journal Year: 2024, Volume and Issue: 21(4), P. 257 - 277

Published: Feb. 7, 2024

Language: Английский

---

Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives

Cancers, Journal Year: 2024, Volume and Issue: 16(7), P. 1276 - 1276

Published: March 25, 2024

Despite decades of research and the best up-to-date treatments, grade 4 Glioblastoma (GBM) remains uniformly fatal with a patient median overall survival less than 2 years. Recent advances in immunotherapy have reignited interest utilizing immunological approaches to fight cancer. However, current immunotherapies so far not met anticipated expectations, achieving modest results their journey from bench bedside for treatment GBM. Understanding intrinsic features GBM is crucial importance development effective antitumoral strategies improve life expectancy conditions. In this review, we provide comprehensive overview distinctive characteristics that significantly influence conventional therapies immune-based approaches. Moreover, present an immunotherapeutic currently undergoing clinical evaluation treatment, specific emphasis on those advancing phase 3 studies. These encompass immune checkpoint inhibitors, adoptive T cell therapies, vaccination (i.e., RNA-, DNA-, peptide-based vaccines), virus-based Finally, explore novel innovative future prospects field

Language: Английский

---

The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives

International Journal of Radiation Oncology*Biology*Physics, Journal Year: 2024, Volume and Issue: 118(5), P. 1404 - 1421

Published: Jan. 5, 2024

Language: Английский

---

Next-generation cancer vaccines and emerging immunotherapy combinations

Trends in cancer, Journal Year: 2024, Volume and Issue: 10(8), P. 749 - 769

Published: Aug. 1, 2024

Language: Английский

---

Gliomas in adults: Guidance on Investigations, Diagnosis, Treatment & Surveillance

Clinical Medicine, Journal Year: 2024, Volume and Issue: 24(5), P. 100240 - 100240

Published: Sept. 1, 2024

Primary brain tumours are rare but carry a significant morbidity and mortality burden. Malignant gliomas the most common subtype their incidence is increasing within our ageing population. The diagnosis treatment of involves substantial interplay between multiple specialties, including general medical physicians, radiologists, pathologists, surgeons, oncologists allied health professionals. At any point along this pathway, patients can present to acute medicine with complications cancer or anti-cancer therapy. Increasing awareness malignant among physicians paramount delivering prompt radiological histopathological diagnoses, facilitating access earlier individualised options allows for effective recognition management anticipated complications. This article discusses evidence-based real-world practice gliomas, encompassing patient presentation, diagnostic pathways, treatments complications, prognosis guide outside specialist centres.

Language: Английский

---

Immune Cell Interplay in the Fight Against GBM

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 817 - 817

Published: Feb. 26, 2025

Despite multimodal therapies, the treatment of glioblastoma remains challenging. In addition to very complex mechanisms cancer cells, including specialized phenotypes that enable them proliferate, invade tissues, and evade immunosurveillance, they exhibit a pronounced resistance chemo- radiotherapy. More advanced tumors create hypoxic environment supports their proliferation survival, while robust angiogenesis ensures constant supply nutrients. GBM, these structures are contribute creation maintenance highly immunosuppressive microenvironment promotes tumor growth immune escape. addition, high accumulation tumor-infiltrating leukocytes other expression checkpoint molecules, low mutational burden, i.e., number neoantigens, hallmarks GBM challenge therapeutic approaches. Here, we review exploits support potential treatments. These include new chemotherapeutics, treating fields, small compounds targeting or blockers tyrosine kinases inhibit cell survival. focus on immunotherapies such as blockade in particular vaccination with dendritic cells CAR-T which can either kill directly bypass immunosuppression by modulating boosting patient's own response.

Language: Английский

---

Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy

Aging Cell, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

Immunotherapy has transformed the landscape of cancer treatment, with T cell-based strategies at forefront this revolution. However, durability these responses is frequently undermined by two intertwined phenomena: cell exhaustion and senescence. While driven chronic antigen exposure in immunosuppressive tumor microenvironment, leading to a reversible state diminished functionality, senescence reflects more permanent, age- or stress-induced arrest cellular proliferation effector capacity. Together, processes represent formidable barriers sustained anti-tumor immunity. In review, we dissect molecular underpinnings senescence, revealing how dysfunctions synergistically contribute immune evasion resistance across range solid tumors. We explore cutting-edge therapeutic approaches aimed rewiring exhausted senescent phenotypes. These include advances checkpoint blockade, engineering "armored" CAR-T cells, senolytic therapies that selectively eliminate novel interventions reinvigorate system's capacity for eradication. By spotlighting emerging target both provide forward-looking perspective on potential harness rejuvenation. This comprehensive review outlines next frontier immunotherapy: unlocking durable overcoming intrinsic aging exhaustion, ultimately paving way transformative breakthroughs.

Language: Английский

---

Empowering standardization of cancer vaccines through ontology: enhanced modeling and data analysis

Journal of Biomedical Semantics, Journal Year: 2024, Volume and Issue: 15(1)

Published: June 18, 2024

The exploration of cancer vaccines has yielded a multitude studies, resulting in diverse collection information. heterogeneity vaccine data significantly impedes effective integration and analysis. While CanVaxKB serves as pioneering database for over 670 manually annotated vaccines, it is important to distinguish that database, on its own, does not offer the structured relationships standardized definitions found an ontology. Recognizing this, we expanded Vaccine Ontology (VO) include those present were initially covered, enhancing VO's capacity systematically define interrelate vaccines. An ontology design pattern (ODP) was first developed applied semantically represent various capturing their associated entities relations. By applying ODP, generated template tabular format converted into RDF/OWL generation terms VO. '12MP vaccine' used example demonstrate application ODP. VO also reuses reference such diseases hosts. Description Logic (DL) SPARQL query scripts based different vaccine's features versatility representation. Additionally, ontological modeling illustrate related concepts studies in-depth A vaccine-specific view, referred "CVO," generated, contains 928 classes including 704 CVO OWL file publicly available on: http://purl.obolibrary.org/obo/vo/cvo.owl , sharing applications. To facilitate standardization, integration, analysis data, model We pipeline automate inclusion This only enriches data's standardization but leverages deepen information, maximizing benefits researchers clinicians. VO-cancer GitHub website is: https://github.com/vaccineontology/VO/tree/master/CVO .

Language: Английский

---

The challenges and clinical landscape of glioblastoma immunotherapy

CNS Oncology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Oct. 29, 2024

Glioblastoma is associated with a dismal prognosis the standard of care involving surgery, radiation therapy and temozolomide chemotherapy. This review investigates features that make glioblastoma difficult to treat results immunotherapy clinical trials so far. There have been over hundred in glioblastoma. We report survival-related outcomes every Phase III trial online published we could find at time writing. To date, DCVax-L vaccine only shown statistically significant increased median survival compared standard-of-care trial: 19.3 months versus 16.5 months. However, this used an external control group compare intervention which limits its quality evidence. In conclusion, requires further investigation determine significance improving disease survival.

Language: Английский

---

Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 23, 2024

Language: Английский

---